Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Executive Summary

Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.

You may also be interested in...



At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.

Trump's Budget Surprise: FDA Gains 13% Increase

President Trump's FY 2019 budget request includes $473m in new non-user fee revenue for the US agency, a reversal of the previous year's request.

US FDA Looks To Proactively Update Old Generic Drug Labels Under Pilot

Concept mentioned during Gottlieb’s 'star' turn at Davos may sound similar to now-withdrawn generic labeling rule, but actually appears based on a proposal from the Friends of Cancer Research to get current clinical guidelines reflected on labels.

Related Content

Topics

UsernamePublicRestriction

Register

GB002278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel